Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | NCF1 | P14598 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GALR3 | O60755 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6788358 | 0.87 | CYP2C19 (0.56) | CYP1A2NCF1CYP2C19SMN1; SMN2HTT | |
| SCHEMBL8232676 | 0.84 | CYP1A2 (0.62) | CYP1A2NCF1CYP2C19SMN1; SMN2HTT | |
| SCHEMBL6784056 | 0.83 | CYP1A2 (0.56) | CYP1A2NCF1CYP2C19SMN1; SMN2HTT | |
| SCHEMBL3881739 | 0.83 | LMNA (0.56) | CYP1A2NCF1CYP2C19SMN1; SMN2HTT | |
| SCHEMBL994597 | 0.82 | CYP1A2 (0.60) | CYP1A2NCF1CYP2C19SMN1; SMN2HTT | |
| SCHEMBL3921968 | 0.82 | CYP1A2 (0.60) | CYP1A2NCF1CYP2C19SMN1; SMN2HTT | |
| SCHEMBL6494917 | 0.82 | CYP1A2 (0.60) | CYP1A2NCF1CYP2C19SMN1; SMN2HTT | |
| SCHEMBL6494921 | 0.82 | CYP1A2 (0.60) | CYP1A2NCF1CYP2C19SMN1; SMN2HTT | |
| SCHEMBL265139 | 0.82 | NCF1 (0.61) | CYP1A2NCF1CYP2C19SMN1; SMN2HTT | |
| SCHEMBL6985541 | 0.82 | CYP1A2 (0.60) | CYP1A2NCF1CYP2C19SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109776407-B | Preparation method of 2-methyl-4-hydroxymethyl quinoline and derivatives thereof | 济南大学 | 2022-04-12 | — | — | CN | claimed |
| CN-109776407-A | A kind of preparation method of 2- methyl -4- hydroxymethyl quinoline and its derivative | 济南大学 | 2019-05-21 | — | — | CN | claimed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | claimed |
| CN-109776407-B | Preparation method of 2-methyl-4-hydroxymethyl quinoline and derivatives thereof | 济南大学 | 2022-04-12 | — | — | CN | disclosed |
| CN-109776407-B | Preparation method of 2-methyl-4-hydroxymethyl quinoline and derivatives thereof | 济南大学 | 2022-04-12 | — | — | CN | disclosed |
| CN-109467549-B | Quinoline-substituted chalcone compound, preparation method and application thereof | 中国药科大学 | 2021-02-09 | — | — | CN | disclosed |
| CN-109776407-A | A kind of preparation method of 2- methyl -4- hydroxymethyl quinoline and its derivative | 济南大学 | 2019-05-21 | — | — | CN | disclosed |
| CN-109776407-A | A kind of preparation method of 2- methyl -4- hydroxymethyl quinoline and its derivative | 济南大学 | 2019-05-21 | — | — | CN | disclosed |
| CN-109467549-A | Quinoline replaces chalcone compounds, preparation method and the usage | 中国药科大学 | 2019-03-15 | — | — | CN | disclosed |
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE HOLDINGS CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1087937-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1054877-A1 | NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000059285-A2 | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999065867-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999041246-A1 | NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | MMP9, MMP3, MMP12 | CYP1A2 173/4885NCF1 1966/4885CYP2C19 349/4885 |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | CYP1A2 173/4885NCF1 1966/4885CYP2C19 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.